General Information of This Target
Target ID
PATR0CMGNI
Target Name
Protein cereblon (CRBN)
Gene Name
CRBN
Gene ID
51185
Synonym
AD-006
Sequence
MAGEGDQQDAAHNMGNHLPLLPAESEEEDEMEVEDQDSKEAKKPNIINFDTSLPTSHTYL
GADMEEFHGRTLHDDDSCQVIPVLPQVMMILIPGQTLPLQLFHPQEVSMVRNLIQKDRTF
AVLAYSNVQEREAQFGTTAEIYAYREEQDFGIEIVKVKAIGRQRFKVLELRTQSDGIQQA
KVQILPECVLPSTMSAVQLESLNKCQIFPSKPVSREDQCSYKWWQKYQKRKFHCANLTSW
PRWLYSLYDAETLMDRIKKQLREWDENLKDDSLPSNPIDFSYRVAACLPIDDVLRIQLLK
IGSAIQRLRCELDIMNKCTSLCCKQCQETEITTKNEIFSLSLCGPMAAYVNPHGYVHETL
TVYKACNLNLIGRPSTEHSWFPGYAWTVAQCKICASHIGWKFTATKKDMSPQKFWGLTRS
ALLPTIPDTEDEISPDKVILCL

    Click to Show/Hide
Family
the CRBN family
Function
Substrate recognition component of a DCX (DDB1-CUL4-X-box) E3 protein ligase complex that mediates the ubiquitination and subsequent proteasomal degradation of target proteinssuch as MEIS2 or ILF2. Normal degradation of key regulatory proteins is required for normal limb outgrowth and expression of the fibroblast growth factor FGF8. Maintains presynaptic glutamate release and consequently cognitive functionssuch as memory and learningby negatively regulating large-conductance calcium-activated potassium (BK) channels in excitatory neurons. Likely to function by regulating the assembly and neuronal surface expression of BK channels via its interaction with KCNT1. May also be involved in regulating anxiety-like behaviors via a BK channel-independent mechanism. Plays a negative role in TLR4 signaling by interacting with TRAF6 and ECSITleading to inhibition of ECSIT ubiquitinationan important step of the signaling.

    Click to Show/Hide
Uniprot Entry
CRBN_HUMAN
HGNC ID
HGNC:30185
KEGG ID
hsa:51185
Full List of The ADC Related to This Target
Investigative
Click To Hide/Show 90 ADC Related to This Stage
ADC Info ADC Name Antibody Antigen Payload Linker Ref
Gemtuzumab-Compound (Ie)
Gemtuzumab
Myeloid cell surface antigen CD33 (CD33)
NeoDegrader P1
Gemtuzumab-Compound (Ie) linker
[1]
Rituximab-Compound (la) DAR 8
Rituximab
B-lymphocyte antigen CD20 (MS4A1)
NeoDegrader P1
Rituximab-Compound (la) linker
[2]
Pertuzumab-Compound(la)
Pertuzumab
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
NeoDegrader P1
Pertuzumab-Compound(la) linker
[2]
Trastuzumab-Compound (la) DAR 1.6
Trastuzumab
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
NeoDegrader P1
Trastuzumab-Compound (la) DAR 1.6 linker
[2]
Trastuzumab-Compound (la) DAR 8
Trastuzumab
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
NeoDegrader P1
Trastuzumab-Compound (la) DAR 8 linker
[2]
Pertuzumab-Compound (la) DAR 8
Pertuzumab
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
NeoDegrader P1
Pertuzumab-Compound (la) DAR 8 linker
[2]
OR000213-Compound (Ia)
OR000213
Myeloid cell surface antigen CD33 (CD33)
NeoDegrader P1
OR000213-Compound (Ia) linker
[2]
HuMy9-6IgG1-Compound (la) DAR 8
huMy9-6 IgG1
Myeloid cell surface antigen CD33 (CD33)
NeoDegrader P1
huMy9-6IgG1-Compound (la) DAR 8 linker
[2]
Lintuzumab IgG1-Compound (la) DAR 8
Lintuzumab
Myeloid cell surface antigen CD33 (CD33)
NeoDegrader P1
Lintuzumab IgG1-Compound (la) DAR 8 linker
[2]
OR000213-Compound(la) DAR 8
OR000213
Myeloid cell surface antigen CD33 (CD33)
NeoDegrader P1
OR000213-Compound(la) DAR 8 linker
[2]
HuMy9-6 IgG1-Compound (la) DAR 1.9
huMy9-6 IgG1
Myeloid cell surface antigen CD33 (CD33)
NeoDegrader P1
huMy9-6 IgG1-Compound (la) DAR 1.9 linker
[2]
HuMy9-6IgG1-Compound (la) DAR3.9
huMy9-6 IgG1
Myeloid cell surface antigen CD33 (CD33)
NeoDegrader P1
huMy9-6IgG1-Compound (la) DAR3.9 linker
[2]
HuMy9-6IgG1-Compound(la) DAR 5.5
huMy9-6 IgG1
Myeloid cell surface antigen CD33 (CD33)
NeoDegrader P1
huMy9-6IgG1-Compound(la) DAR 5.5 linker
[2]
OR000213-Compound (la) DAR 1.2
OR000213
Myeloid cell surface antigen CD33 (CD33)
NeoDegrader P1
OR000213-Compound (la) DAR 1.2 linker
[2]
OR000213-Compound(la) DAR 1.8
OR000213
Myeloid cell surface antigen CD33 (CD33)
NeoDegrader P1
OR000213-Compound(la) DAR 1.8 linker
[2]
OR000213-Compound(la) DAR 2.3
OR000213
Myeloid cell surface antigen CD33 (CD33)
NeoDegrader P1
OR000213-Compound(la) DAR 2.3 linker
[2]
Trastuzumab-Compound (Ib) DAR1.5
Trastuzumab
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
NeoDegrader P3
Trastuzumab-Compound (Ib) DAR1.5 linker
[2]
Trastuzumab-Compound (lc)
Trastuzumab
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
NeoDegrader P4
Trastuzumab-Compound (lc) linker
[2]
Rituximab-Compound (lc)
Rituximab
B-lymphocyte antigen CD20 (MS4A1)
NeoDegrader P4
Rituximab-Compound (lc) linker
[2]
Pertuzumab-Compound(lc)
Pertuzumab
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
NeoDegrader P4
Pertuzumab-Compound(lc) linker
[2]
Trastuzumab-Compound (lc) DAR 8
Trastuzumab
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
NeoDegrader P4
Trastuzumab-Compound (lc) DAR 8 linker
[2]
Pertuzumab-Compound (lc) DAR 8
Pertuzumab
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
NeoDegrader P4
Pertuzumab-Compound (lc) DAR 8 linker
[2]
Trastuzumab-Compound (ld) DAR 1.6
Trastuzumab
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
NeoDegrader P1
Trastuzumab-Compound (ld) DAR 1.6 linker
[2]
HuMy9-6IgG1-Compound (ld) DAR 8
huMy9-6 IgG1
Myeloid cell surface antigen CD33 (CD33)
NeoDegrader P1
huMy9-6IgG1-Compound (ld) DAR 8 linker
[2]
Lintuzumab IgG1-Compound (ld) DAR 8
Lintuzumab
Myeloid cell surface antigen CD33 (CD33)
NeoDegrader P1
Lintuzumab IgG1-Compound (ld) DAR 8 linker
[2]
Trastuzumab-Compound (le)
Trastuzumab
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
NeoDegrader P1
Trastuzumab-Compound (le) linker
[2]
Rituximab-Compound (le)
Rituximab
B-lymphocyte antigen CD20 (MS4A1)
NeoDegrader P1
Rituximab-Compound (le) linker
[2]
Pertuzumab-Compound (le)
Pertuzumab
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
NeoDegrader P1
Pertuzumab-Compound (le) linker
[2]
Trastuzumab-Compound (lf)
Trastuzumab
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
NeoDegrader P6
Trastuzumab-Compound (lf) linker
[2]
Rituximab-Compound (lf)
Rituximab
B-lymphocyte antigen CD20 (MS4A1)
NeoDegrader P6
Rituximab-Compound (lf) linker
[2]
Pertuzumab-Compound (lf)
Pertuzumab
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
NeoDegrader P6
Pertuzumab-Compound (lf) linker
[2]
Trastuzumab-Compound (lg)
Trastuzumab
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
NeoDegrader P2
Trastuzumab-Compound (lg) linker
[2]
Rituximab-Compound (lg)
Rituximab
B-lymphocyte antigen CD20 (MS4A1)
NeoDegrader P2
Rituximab-Compound (lg) linker
[2]
Pertuzumab-Compound (lg)
Pertuzumab
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
NeoDegrader P2
Pertuzumab-Compound (lg) linker
[2]
Trastuzumab-Compound (lh)
Trastuzumab
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
NeoDegrader P13
Trastuzumab-Compound (lh) linker
[2]
Rituximab-Compound (lh)
Rituximab
B-lymphocyte antigen CD20 (MS4A1)
NeoDegrader P13
Rituximab-Compound (lh) linker
[2]
Pertuzumab-Compound (lh)
Pertuzumab
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
NeoDegrader P13
Pertuzumab-Compound (lh) linker
[2]
Trastuzumab-Compound (li)
Trastuzumab
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
NeoDegrader P1
Trastuzumab-Compound (li) linker
[2]
Rituximab-Compound (li)
Rituximab
B-lymphocyte antigen CD20 (MS4A1)
NeoDegrader P1
Rituximab-Compound (li) linker
[2]
Pertuzumab-Compound (li)
Pertuzumab
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
NeoDegrader P1
Pertuzumab-Compound (li) linker
[2]
Trastuzumab-Compound (lj)
Trastuzumab
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
NeoDegrader P1
Trastuzumab-Compound (lj) linker
[2]
Rituximab-Compound (lj)
Rituximab
B-lymphocyte antigen CD20 (MS4A1)
NeoDegrader P1
Rituximab-Compound (lj) linker
[2]
Pertuzumab-Compound (lj)
Pertuzumab
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
NeoDegrader P1
Pertuzumab-Compound (lj) linker
[2]
Trastuzumab-Compound (lk)
Trastuzumab
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
NeoDegrader P14
Trastuzumab-Compound (lk) linker
[2]
Rituximab-Compound (lk)
Rituximab
B-lymphocyte antigen CD20 (MS4A1)
NeoDegrader P14
Rituximab-Compound (lk) linker
[2]
Pertuzumab-Compound (lk)
Pertuzumab
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
NeoDegrader P14
Pertuzumab-Compound (lk) linker
[2]
Trastuzumab-Compound (ll)
Trastuzumab
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
NeoDegrader P14
Trastuzumab-Compound (ll) linker
[2]
Rituximab-Compound (ll)
Rituximab
B-lymphocyte antigen CD20 (MS4A1)
NeoDegrader P14
Rituximab-Compound (ll) linker
[2]
Pertuzumab-Compound (ll)
Pertuzumab
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
NeoDegrader P14
Pertuzumab-Compound (ll) linker
[2]
Trastuzumab-Compound (lm)
Trastuzumab
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
NeoDegrader P14
Trastuzumab-Compound (lm) linker
[2]
Rituximab-Compound (lm)
Rituximab
B-lymphocyte antigen CD20 (MS4A1)
NeoDegrader P14
Rituximab-Compound (lm) linker
[2]
Pertuzumab-Compound (lm)
Pertuzumab
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
NeoDegrader P14
Pertuzumab-Compound (lm) linker
[2]
Rituximab-Compound (la) DAR 4
Rituximab
B-lymphocyte antigen CD20 (MS4A1)
NeoDegrader P1
Rituximab-Compound (la) linker
[2]
HuAT12/5-Compound (Ia)
HuAT12/5
ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 (CD38)
NeoDegrader P1
HuAT12/5-Compound (Ia) linker
[2]
Isatuximab-Compound (Ia)
Isatuximab
ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 (CD38)
NeoDegrader P1
Isatuximab-Compound (Ia) linker
[2]
Daratumumab-Compound (Ia)
Daratumumab
ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 (CD38)
NeoDegrader P1
Daratumumab-Compound (Ia) linker
[2]
Indatuximab-Compound (Ia)
Indatuximab
ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 (CD38)
NeoDegrader P1
Indatuximab-Compound (Ia) linker
[2]
Belantamab-Compound (Ia)
Belantamab
Tumor necrosis factor receptor superfamily member 17 (TNFRSF17)
NeoDegrader P1
Belantamab-Compound (Ia) linker
[2]
Sacituzumab-Compound (Ia)
Sacituzumab
Tumor-associated calcium signal transducer 2 (TACSTD2)
NeoDegrader P1
Sacituzumab-Compound (Ia) linker
[2]
U3-1784-Compound (Ia)
U3-1784
Fibroblast growth factor receptor 4 (FGFR4)
NeoDegrader P1
U3-1784-Compound (Ia) linker
[2]
Cetuximab-Comound (Ia)
Cetuximab
Epidermal growth factor receptor (EGFR)
NeoDegrader P1
Cetuximab-Comound (Ia) linker
[2]
Olaratumab-Compound (Ia)
Olaratumab
Platelet-derived growth factor receptor alpha (PDGFRA)
NeoDegrader P1
Olaratumab-Compound (Ia) linker
[2]
Ontuxizumab-Compound (Ia)
Ontuxizumab
Endosialin (CD248)
NeoDegrader P1
Ontuxizumab-Compound (Ia) linker
[2]
Anti-CD33AB-Compound (Ia)
Anti-CD33AB
Myeloid cell surface antigen CD33 (CD33)
NeoDegrader P1
Anti-CD33AB-Compound (Ia) linker
[1]
Anti-CD33AB-Compound (Ib)
Anti-CD33AB
Myeloid cell surface antigen CD33 (CD33)
NeoDegrader P1
Anti-CD33AB-Compound (Ib) linker
[1]
Anti-CD33AB-Compound (Ic)
Anti-CD33AB
Myeloid cell surface antigen CD33 (CD33)
NeoDegrader P1
Anti-CD33AB-Compound (Ic) linker
[1]
Anti-CD33AB-Compound (Ie)
Anti-CD33AB
Myeloid cell surface antigen CD33 (CD33)
NeoDegrader P1
Anti-CD33AB-Compound (Ie) linker
[1]
Anti-CD33AB-Compound (Ih)
Anti-CD33AB
Myeloid cell surface antigen CD33 (CD33)
NeoDegrader P1
Anti-CD33AB-Compound (Ih) linker
[1]
Gemtuzumab-Compound (Ia)
Gemtuzumab
Myeloid cell surface antigen CD33 (CD33)
NeoDegrader P1
Gemtuzumab-Compound (Ia) linker
[1]
Gemtuzumab-Compound (Ib)
Gemtuzumab
Myeloid cell surface antigen CD33 (CD33)
NeoDegrader P1
Gemtuzumab-Compound (Ib) linker
[1]
Gemtuzumab-Compound (Ic)
Gemtuzumab
Myeloid cell surface antigen CD33 (CD33)
NeoDegrader P1
Gemtuzumab-Compound (Ic) linker
[1]
Gemtuzumab-Compound (Ih)
Gemtuzumab
Myeloid cell surface antigen CD33 (CD33)
NeoDegrader P1
Gemtuzumab-Compound (Ih) linker
[1]
HuMy9-6-IgG4-S228P-Compound (Ia)
huMy9-6-IgG4-S228P
Myeloid cell surface antigen CD33 (CD33)
NeoDegrader P1
huMy9-6-IgG4-S228P-Compound (Ia) linker
[1]
HuMy9-6-IgG4-S228P-Compound (Ib)
huMy9-6-IgG4-S228P
Myeloid cell surface antigen CD33 (CD33)
NeoDegrader P1
huMy9-6-IgG4-S228P-Compound (Ib) linker
[1]
HuMy9-6-IgG4-S228P-Compound (Ic)
huMy9-6-IgG4-S228P
Myeloid cell surface antigen CD33 (CD33)
NeoDegrader P1
huMy9-6-IgG4-S228P-Compound (Ic) linker
[1]
HuMy9-6-IgG4-S228P-Compound (Ie)
huMy9-6-IgG4-S228P
Myeloid cell surface antigen CD33 (CD33)
NeoDegrader P1
huMy9-6-IgG4-S228P-Compound (Ie) linker
[1]
HuMy9-6-IgG4-S228P-Compound (Ih)
huMy9-6-IgG4-S228P
Myeloid cell surface antigen CD33 (CD33)
NeoDegrader P1
huMy9-6-IgG4-S228P-Compound (Ih) linker
[1]
Anti-CD33 AB1 Compound (Ia)
Anti-CD33 AB1
Myeloid cell surface antigen CD33 (CD33)
NeoDegrader P1
Anti-CD33 AB1 Compound (Ia) linker
[3]
Anti-CD33 AB1 Compound (Ib)
Anti-CD33 AB1
Myeloid cell surface antigen CD33 (CD33)
NeoDegrader P1
Anti-CD33 AB1 Compound (Ib) linker
[3]
Anti-CD33 AB1 Compound (Ic)
Anti-CD33 AB1
Myeloid cell surface antigen CD33 (CD33)
NeoDegrader P1
Anti-CD33 AB1 Compound (Ic) linker
[3]
Anti-CD33 AB1 Compound (Id)
Anti-CD33 AB1
Myeloid cell surface antigen CD33 (CD33)
NeoDegrader P1
Anti-CD33 AB1 Compound (Id) linker
[3]
Anti-CD33 AB1 Compound (Ie)
Anti-CD33 AB1
Myeloid cell surface antigen CD33 (CD33)
NeoDegrader P1
Anti-CD33 AB1 Compound (Ie) linker
[3]
Anti-CD33 AB1 Compound (If)
Anti-CD33 AB1
Myeloid cell surface antigen CD33 (CD33)
NeoDegrader P6
Anti-CD33 AB1 Compound (If) linker
[3]
Anti-CD33 AB1 Compound (Ig)
Anti-CD33 AB1
Myeloid cell surface antigen CD33 (CD33)
NeoDegrader P2
Anti-CD33 AB1 Compound (Ig) linker
[3]
Anti-CD33 AB1 Compound (Ih)
Anti-CD33 AB1
Myeloid cell surface antigen CD33 (CD33)
NeoDegrader P1
Anti-CD33 AB1 Compound (Ih) linker
[3]
Anti-CD33 AB1 Compound (Ii)
Anti-CD33 AB1
Myeloid cell surface antigen CD33 (CD33)
NeoDegrader P1
Anti-CD33 AB1 Compound (Ii) linker
[3]
Anti-CD33 AB1 Compound (Ij)
Anti-CD33 AB1
Myeloid cell surface antigen CD33 (CD33)
NeoDegrader P1
Anti-CD33 AB1 Compound (Ij) linker
[3]
Anti-CD33 AB1 Compound (Ik)
Anti-CD33 AB1
Myeloid cell surface antigen CD33 (CD33)
NeoDegrader P14
Anti-CD33 AB1 Compound (Ik) linker
[3]
Anti-CD33 AB1 Compound (Il)
Anti-CD33 AB1
Myeloid cell surface antigen CD33 (CD33)
NeoDegrader P14
Anti-CD33 AB1 Compound (Il) linker
[3]
Anti-CD33 AB1 Compound (Im)
Anti-CD33 AB1
Myeloid cell surface antigen CD33 (CD33)
NeoDegrader P14
Anti-CD33 AB1 Compound (Im) linker
[3]
References
Ref 1 Neodegrader conjugates; 2021-10-07.
Ref 2 Neodegrader conjugates; 2021-10-07.
Ref 3 Neodegrader-anti-cd33 antibody conjugates; 2022-12-08.